A Phase 2/3, Multicenter, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Bedaquiline (Primary) ; Clarithromycin; Ethambutol; Rifabutin; Rifampicin
- Indications Lung disorders; Mycobacterium avium complex infections
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 17 Jul 2024 Planned primary completion date changed from 23 Sep 2025 to 17 Jul 2025.
- 17 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2023 Status changed from active, no longer recruiting to recruiting.